Business Context and Reporting Period
Company: Black Diamond Therapeutics, Inc. (BDTX)
Filing Type: Form 8-K (Current Report)
Date: September 23, 2024
Context: The Company is an emerging growth company focused on oncology. This filing discloses initial Phase 2 clinical data for its lead candidate, BDTX-1535, in patients with recurrent EGFR-mutant non-small cell lung cancer (NSCLC).
Key Financial Metrics
This Form 8-K is a disclosure of clinical trial results and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The primary material event is the release of preliminary Phase 2 data for BDTX-1535 as of an August 17, 2024 cutoff:
- Dose Selection: 200 mg daily selected for pivotal clinical development based on pharmacokinetics, safety, and tolerability.
- Safety Profile: Favorable tolerability at 200 mg. Most adverse events were mild or moderate. Common on-target events included rash (70%) and diarrhea (35%). Two cases of grade 3 rash were reported; no grade 4 rash or grade 3/4 diarrhea occurred.
- Efficacy (Objective Response Rate - ORR):
- 42% ORR in 19 patients with known osimertinib resistance mutations (C797S or P-loop alpha-C helix compressing).
- 36% ORR in 22 response-evaluable patients.
- Responses included five confirmed partial responses (PR) and three unconfirmed PRs awaiting scans. One patient converted from PR to an unconfirmed complete response at 8 months.
- Nine patients experienced stable disease.
- Durability: Duration of response was approximately 8 months or more for the first three patients with PR. 14 of 19 patients remain on therapy with a mean follow-up of 4.7 months.
Guidance, Outlook, and Risks
Outlook: Management anticipates advancing BDTX-1535 into pivotal clinical development. The data supports the potential of the drug to address unmet needs in recurrent NSCLC and patients with non-classical EGFR mutations.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual results may differ due to risks outlined in the Company's 2023 Form 10-K, including uncertainties regarding clinical trial outcomes, regulatory feedback, and market opportunities.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed patient demographics and specific mutation types.
- Review the Company's most recent Form 10-K or 10-Q for current cash runway and liquidity status, as this 8-K contains no financial data.
- Monitor upcoming regulatory interactions regarding the registrational pathway for BDTX-1535 in NSCLC.
- Track the confirmation status of the three unconfirmed partial responses and the one unconfirmed complete response.